Less concern of increasing the risk of infections and cancers
Cytokine inhibitors, the most popular bio-therapeutics on the market, can help patients relieve symptoms associated with inflammatory diseases. However, increased risk of infection has often been noted in those inhibitors targeting immune-related cytokines such as TNF-alpha, IL-12/23, IL-6 and IL-17. In contrast, accumulated clinical evidence demonstrated no signs of elevated infection risks post Neihulizumab treatment.
A long-lasting drug-free remission
By effectively eliminating chronic pathogenic T cells, Neihulizumab is likely to achieve a long-lasting remission. One of the limitations of TNF-alpha and IL-17 inhibitors is the lack of long-lasting drug-free remission. Although IL-12/23 inhibitors have longer remission terms of about 3 months, none of the current therapies the goal of a long-lasting and drug-free remission.
Alternative therapy for the patients who either did not respond or lost response to existing therapies
Close to 50% of RA and PsA patients treated with existing cytokine inhibitors for at least 6 months failed to achieve the 50% (ACR50) improvement criteria. Furthermore, more than 50% of patients undergoing long-term treatment of TNF-alpha inhibitors lose response to the drugs. Therefore, an alternative therapeutic agent like Neihulizumab is well positioned to treat those patients who no longer respond to or discontinue the use of these drugs .
A potential standard of treatment for inflammatory diseases that have no effective treatments
Neihulizumab not only showed efficacy in psoriasis but also demonstrated an extraordinarily effectiveness with regards to pain reduction in PsA patients. Current biologics are poor or ineffective at treating diseases like PsA, GvHD, transplantation, inflammatory bowel disease, multiple sclerosis, type I diabetes and allergic diseases. Neihulizumab, however, has great potential to provide meaningful clinical benefits to those patients with unmet medical needs.